Structure Therapeutics (GPCR)

• Market cap: $1.6B
• 1 day: -6.91%
• 5 days: -10.03%
• 1 month: -14.70%
• 3 months: -33.44%
• 6 months: -40.32%
• Year to date: -30.92%
• 1 year: -15.43%
• 5 years: 7.31%
• 10 years: 7.31%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.

Employees: 148

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

83% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 36

75% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 7 (+3) [Q3]

12% more capital invested

Capital invested by funds: $2.38B [Q2] → $2.67B (+$294M) [Q3]

12% more call options, than puts

Call options by funds: $20.8M | Put options by funds: $18.6M

0.19% more ownership

Funds ownership: 35.36% [Q2] → 35.55% (+0.19%) [Q3]

4% less funds holding

Funds holding: 166 [Q2] → 159 (-7) [Q3]

20% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 35

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $65 133% upside
• Avg. target: $89 217% upside
• High target: $118 323% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 105 / 327 met price target	187% upside $80	Buy Reiterated	20 Dec 2024
JMP Securities Jonathan Wolleben 46% 1-year accuracy 34 / 74 met price target	226% upside $91	Market Outperform Reiterated	18 Dec 2024
Cantor Fitzgerald Prakhar Agrawal 17% 1-year accuracy 4 / 24 met price target	133% upside $65	Overweight Reiterated	23 Sept 2024
Morgan Stanley Terence Flynn 25% 1-year accuracy 4 / 16 met price target	323% upside $118	Overweight Initiated	23 Sept 2024